Frontier Biotech

Founded in 2013, Frontier Biotech is a commercial-stage biopharmaceutical company based in China with international visions and global competitiveness, dedicated  to discovery, development, manufacturing and commercialization of innovative medicines for serving the unmet medical needs, including anti-HIV treatment and  pain management. Our first commercial product was approved by NMPA (National Medical Product Agency, the Chinese drug regulatory body) in May 2018 with the priority review and accelerated approval status; two other drug candidates have entered multiple Phase 1 and 2 clinical trials in China and United States.Frontier Biotech has industry-leading expertise in the development of long acting peptide drugs, very experienced management and R&D teams, a GMP-certified manufacturing facility,  talented medical information, international business development and marketing teams, covering the entire chain of innovative drug discovery, preclinical research and development, and global clinical development that enables Frontier Biotech being globally competitive in the field of HIV long-acting treatment and immunotherapy.

Frontier Biotechnologies Inc.(Nanjing)

Nanjing: company headquarter, GMP manufacturing facility for peptide API and finished productsChongqing: R&D and marketingBeijing: Center for clinical research, regulatory, government affairs, mar


Long-acting peptide drug

Frontier Biotech has established a talented R&D team with deep understanding and extensive experience in new drug development. Through the successful development and launch of Aikening?, Frontier Biotech has established a platform in the development of long-acting peptide drugs which lays a solid foundation for enriching its product pipeline and enhancing its global competence.


Develop innovative therapies to better human lives